Full-Time
Confirmed live in the last 24 hours
Develops antibody therapies for viral protection
No salary listed
Senior
Waltham, MA, USA
Invivyd develops antibody-based therapies aimed at protecting individuals with weakened immune systems from viral threats. The company focuses on creating monoclonal antibodies that can provide protection where traditional vaccinations may fall short, particularly for immunocompromised patients. Their main product in development, VYD222, targets the prevention of symptomatic COVID-19 in vulnerable groups, such as organ transplant recipients and those with blood cancers. Invivyd differentiates itself by utilizing advanced technologies like viral surveillance and predictive modeling to optimize their antibody candidates. The company's goal is to safeguard at-risk populations from serious viral infections, starting with COVID-19 and potentially expanding to other viruses like influenza.
Company Size
51-200
Company Stage
IPO
Headquarters
Waltham, Massachusetts
Founded
2020
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
Professional Development Budget
Flexible Work Hours
Invivyd secures a $30 million loan from Silicon Valley Bank to advance its COVID-19 treatment candidate VYD2311.Quiver AI SummaryInvivyd, Inc. announced a $30 million term loan agreement with Silicon Valley Bank to support its biopharmaceutical initiatives, particularly in relation to its candidate monoclonal antibody, VYD2311, which targets COVID-19 and aims to enhance prophylactic and therapeutic options. The loan allows for future capital draw
Adagio, formed in June 2020 to develop drugs for the treatment and prevention of COVID-19, conducted its initial public offering ("IPO") in August 2021.
Biocon is collaborating with US firm Adagio Therapeutics to develop ADG20, an antibody therapy for preventing and treating the Coronavirus and its variants.
Adagio, formed in June 2020 to develop drugs for the treatment and prevention of COVID-19, conducted its initial public offering (“IPO”) in August 2021.
Adagio raised more than US$450 million in funding during its first two years and carried out several clinical trials before disappointment struck when the SARS-CoV-2 virus evolved and the firm’s antibody candidate was no longer effective.